CAR-T Immunotherapy, Chemotherapy Show Promise For Fighting Relapsed Blood Cancer

UNC
20 Jan, 2019 ,

Here Diego, et al. presented preliminary results from a clinical study of investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. Data from the phase Ib/II trial showed that the treatment was safe, and it generated “excellent” responses when used after a specific chemotherapy regimen, researchers reported.

Source